Clinical trials located in


Amsterdam city is located in Netherlands. Currently, 20 clinical trials are being conducted in this city.

Amsterdam, the capital of the Netherlands, is renowned for its historical heritage, intricate canal system, and narrow houses with gabled facades, legacies of the city’s 17th-century Golden Age. Its Museum District houses the Van Gogh Museum, works by Rembrandt and Vermeer at the Rijksmuseum, and modern art at the Stedelijk. Cycling is key to the city’s character, and there are numerous bike paths. The Anne Frank House and the red-light district are also notable aspects of Amsterdam.

  • CT-EU-00121101

    Stem cell transplantation vs. drugs for immunosuppression in early systemic scleroderma

    The clinical trial concerns patients diagnosed with early diffuse systemic sclerosis (dcSSc). This study will compare two treatment strategies: autologous hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy.

    Immunosuppressive therapy includes intravenous cyclophosphamide (CYC) followed by oral mycophenolate mofetil (MMF).

    The aim of the study is to determine which of these two methods is most effective in the treatment of early-stage systemic sclerosis in terms of survival and prevention of organ failure.

    Participation in this study is possible for patients aged 18 to 65 years with diagnosed systemic sclerosis. Patients are divided into two groups: one will receive HSCT immediately, the other will undergo immunosuppressive therapy, with HSCT being a rescue option if there is no response to treatment.

    Measuring effectiveness will be based on multiple health metrics, such as event-free survival, overall survival, disease progression, number of patients requiring rescue therapy, and health-related quality of life.

  • CT-EU-00084342

    Efficacy and safety of MK-7684A and drug combinations in the treatment of selected malignancies in patients with advanced tumors

    The clinical trial covers various types of cancer such as cervical cancer, endometrial cancer (lining of the uterus), head and neck cancer, gallbladder cancer, cholangiocarcinoma, esophageal cancer, triple negative breast cancer, hepatocellular carcinoma, bladder cancer urinary tract, ovarian cancer and stomach cancer.

    The study is testing various therapies combining pembrolizumab and vibostolimab (designated MK-7684A), pembrolizumab alone and combinations with other anticancer drugs such as lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine and oxaliplatin.

    The aim of the study is to determine the safety, tolerability and preliminary effectiveness of various drug combinations in the treatment of selected advanced malignancies

    • Pembrolizumab
    • Pembrolizumab and Vibostolimab/ MK-7684A
    • Lenvatinib
    • Bevacizumab
    • Gemcitabine
    • Cisplatin
    • Carboplatin
    • Capecitabine
    • Oxaliplatin
    • 5-Fluorouracil
    • Paclitaxel
    • Docetaxel
  • Study of the drug EP-104IAR in adults with eosinophilic esophagitis

    The clinical trial concerns patients with eosinophilic esophagitis (EoE) who will be treated with EP-104IAR. EP-104IAR is a long-acting fluticasone-based drug intended for administration by submucosal injection during an endoscopic procedure of the esophagus, stomach and duodenum (EGD).

    The aim of the study is to assess safety, tolerance and the way the body absorbs and eliminates the drug (pharmacokinetics). The study will also evaluate the local effect of the drug on eosinophilic esophagitis disease activity based on endoscopic and histological (tissue) tests.

    The study will involve up to 24 adult participants aged 18 to 75. Participants will be divided into different groups and will receive different doses of EP-104IAR (from 4 mg to 40 mg).

    Individuals participating in the study should have symptoms of eosinophilic esophagitis and must be able to follow study procedures and visit schedules. Participants should not have other esophageal diseases or mucosal infections.

    It is aimed at patients who are ready and able to provide informed consent to participate in the study. During the study, doctors will monitor the patients’ health and carefully assess the effects of the therapy.

    • EP-104IAR
  • Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Testing Gantenerumab and Drug Combinations for Early Onset Alzheimer’s Disease in Families with Genetic Mutations

    This study focuses on Alzheimer’s disease, particularly an early onset type caused by a genetic mutation inherited dominantly. Various therapies will be tested, including Gantenerumab, Solanezumab, Etalanetug, and Lecanemab. The purpose is to assess the safety, tolerability, and effectiveness of these treatments in slowing the progression or improving markers of the disease.

    The study targets individuals who either have a mutation causing Alzheimer’s disease or are at risk of having such a mutation. Participants can be without symptoms or have mild signs of dementia. Both actual medications and placebo will be used to compare the effectiveness of the treatments.

    Gantenerumab is administered subcutaneously (under the skin) every four weeks, while Solanezumab is given through intravenous (IV) infusion every four weeks. Etalanetug and Lecanemab are also administered intravenously. The study design includes different stages, where the participants and research staff may or may not know which specific treatment the participant is receiving, depending on the mutation and the drug being tested.

    This adaptive study aims to find effective treatments by testing multiple therapies. The study will analyze biomarkers (biological markers) from imaging and body fluids and assess clinical and cognitive outcomes to see if the treatments are working on a biological and clinical level. After the main treatment phase, there is an option for participants to receive the active drug in an open-label extension phase.

    • Etalanetug
    • Gantenerumab
    • Solanezumab
    • Lecanemab
  • Study of R3R01 for Kidney Conditions: Alport Syndrome and FSGS

    This study focuses on treating Alport Syndrome and Focal Segmental Glomerulosclerosis (FSGS), which are both kidney diseases. The therapy being tested uses a drug called R3R01.

    The study aims to determine if R3R01 can improve kidney function and reduce damage in patients with these conditions. Participants will receive R3R01 for 12 weeks, and researchers will observe the changes in protein levels in their urine, kidney function, and any side effects. This study is designed to evaluate the safety, tolerability, and effectiveness of R3R01 in these patients.

    • R3R01
  • Study of JNJ-79635322 for Multiple Myeloma and Amyloidosis

    This study is investigating a new drug called JNJ-79635322, which is a trispecific antibody. The main goal of this study is to establish a recommended dose and schedule of drug administration that will be safe for participants. This medicine is intended for people with relapsed or refractory multiple myeloma or previously treated light chain (AL) amyloidosis.

    In the first part of the study, called dose escalation, doctors will gradually increase the dose of the medicine to find the highest dose that is well tolerated. In the second part, called dose expansion, the medicine will be administered at a previously established dose and doctors will monitor the safety and tolerability of the medicine in different groups of patients.

    JNJ-79635322 will be administered as a subcutaneous injection. During the study, doctors will carefully monitor any side effects and abnormal laboratory test results. The most important thing is to ensure the safety of participants and find the optimal dose of the drug.

    • JNJ-79635322
  • Gene Therapy Study for Adrenomyeloneuropathy (AMN)

    This here clinical trial is aimin’ to test out a new gene therapy called SBT101 for folks sufferin’ from a rare condition called adrenomyeloneuropathy (AMN). AMN is caused by a mutation in the ABCD1 gene, which leads to problems with the nervous system and muscles.

    The study will involve givin’ a single dose of SBT101 directly into the spinal fluid through a procedure called intrathecal administration. SBT101 contains a healthy copy of the ABCD1 gene, which the researchers hope will help treat the symptoms of AMN.

    The trial will have two parts. The first part will last 2 years, where some folks will get the real SBT101 treatment, while others will get an imitation procedure. The main goal here is to check the safety of SBT101 and see if it might be slowin’ down the progression of AMN.

    After them 2 years, the second part kicks in for another 3 years, where all the patients who got SBT101 will be monitored for long-term safety. Those who didn’t get the real treatment initially will have the chance to receive SBT101 too, if the data looks promisin’.

  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Personalized T-cell therapy (NEO-PTC-01) for the treatment of patients with unresectable melanoma or metastatic melanoma

    This clinical trial aims to investigate the safety and activity of NEO-PTC-01, which is an autologous personalized T-cell (PTC) product for adoptive cell therapy. Adoptive cell therapy is a type of immunotherapy that uses cells from a patient’s immune system to fight diseases such as cancer. This therapy involves isolating, modifying and multiplying specific immune cells and then administering them to the patient. NEO-PTC-01 is produced outside the body and targets neoantigens displayed on and within the patient’s tumor.

    The study will be conducted in two parts: Part 1 (dose finding) and Part 2 (dose expansion). Two doses of NEO-PTC-01 will be tested in the dose finding portion. Additionally, interleukin (IL)-2 administration and anti-PD-1 antibody therapy are planned.

    Researchers will primarily observe how many patients experience any side effects or adverse events, whether they are mild or serious. To ensure patient safety, they will be under constant care of specialists.

    • An Anti-Programmed Death-1 Antibody (αPD-1)
    • NEO-PTC-01
    • IL-2
  • A study comparing the combination of lifileucel plus pembrolizumab with pembrolizumab alone in the treatment of unresectable, advanced melanoma

    The aim of this study is to test a new treatment for people with advanced melanoma, a serious form of skin cancer that has spread to other parts of the body. The new treatment combines two different therapies: lifileucel, made from the patient’s own immune cells called tumor-infiltrating lymphocytes, and pembrolizumab, a type of immunotherapy drug that helps the body’s immune system fight cancer.

    The study will compare the effectiveness and safety of this combination treatment with pembrolizumab alone. Patients who initially received only pembrolizumab and whose cancer worsened will have the option to switch treatment and receive lifileucel monotherapy.

    The main goals of the study are to see whether the combination treatment can improve the objective response rate, which measures how many patients have had their tumors shrink, and progression-free survival, which is how long patients live without their cancer getting worse. To evaluate the results of the study, patients will be followed for up to 5 years.

    To be eligible for this trial, patients must have advanced melanoma that cannot be surgically removed or has spread to other organs. Additionally, patients cannot be previously treated for metastatic disease, although some prior therapies for earlier stages of melanoma are permitted.

    • Lifileucel
    • Pembrolizumab
  • Study of Fidrisertib/IPN60130 in the treatment of Fibrodysplasia Ossificans Progressiva (FOP)

    The aim of this study is to test a new drug called fidrisertib (also known as IPN60130) to treat a rare disease called Fibrodysplasia Ossificans Progressiva, or FOP. FOP is a grave disease that causes bones to start growing in places they shouldn’t, such as muscles and soft tissues. This causes a lot of pain, swelling, and stiffness in the joints, making movement difficult.

    In the study, some participants will be given the new drug fidrisertib at two different doses, and others will be given a dummy treatment called a placebo. Researchers will monitor the situation closely, performing special tests called low-dose whole-body computed tomography (WBCT) to measure new bone growth. For some older participants, they may also use another type of test called fluorine-18-labeled sodium fluoride positron emission tomography – computed tomography to check bone growth.

    • IPN60130
    • placebo
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Sparsentan treatment study for children with Kidney Diseases

    This study involves children with kidney diseases that lead to high levels of protein in the urine. These diseases include Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The study will use a drug called Sparsentan, administered as an oral suspension or tablet.

    The goal is to determine if Sparsentan is safe and effective for these children. Participants will receive Sparsentan for 112 weeks, and their progress will be monitored to see if protein levels in their urine decrease and if their overall health improves. The study is open-label, meaning all participants will know they are receiving the drug.

    • Sparsentan
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab

See more clinical trials in other cities in Netherlands: